Cargando…
A Case of Escherichia coli Hemolytic Uremic Syndrome in a 10-Year-Old Male With Severe Neurologic Involvement Successfully Treated With Eculizumab
Hemolytic uremic syndrome (HUS) can be classified as typical and atypical, and the treatment recommendations currently differ between the 2 types. Eculizumab is recommended as first-line treatment for atypical HUS; however, its use in typical HUS has been controversial. We report a case of a 10-year...
Autores principales: | Rasa, Malia, Musgrave, James, Abe, Keith, Tanaka, Len, Xoinis, Konstantine, Shiramizu, Bruce, Foskett, Gretchen, Lau, Rhiana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680941/ https://www.ncbi.nlm.nih.gov/pubmed/29152520 http://dx.doi.org/10.1177/2324709617741144 |
Ejemplares similares
-
Severe Neurological Involvement in an Adult with Shiga Toxin-Producing Escherichia coli-Hemolytic Uremic Syndrome Treated with Eculizumab
por: Vanesse, Pauline, et al.
Publicado: (2023) -
Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement
por: Pape, Lars, et al.
Publicado: (2016) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018) -
Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab
por: Ebrahem, Rawaa, et al.
Publicado: (2017)